Boehringer Ingelheim Opens New R&D Center in Basel
NBE Therapeutics (NBE), a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.
Antibody-Drug Conjugates (ADC)
HAS Acquires Cerbios-Pharma
HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
Axplora Expands Capabilities at Le Mans Site
Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).
Samsung Biologics Signs Manufacturing Deal with European Pharmaceutical Company
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
Lonza to Expand Bioconjugation in Visp, Switzerland
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.
Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.
Safety and Innovation: Navigating the Challenges of Antibody-Drug Conjugates
This eBook provides scientists with more information on antibody–drug conjugates (ADCs), allowing you to further your research in this field.
Daiichi Sankyo and MSD Expand Global Collaboration
Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.
How Biotechnological Advances are Transforming Monoclonal Antibody Production
This Article Collection aims to offer scientists a wealth of information on monoclonal antibody (mAb) therapy, enabling you to advance your research in this field.
Johnson & Johnson to Acquire Ambrx
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired.
Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide
Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where Daiichi Sankyo retains exclusive rights. Merck to pay Daiichi Sankyo up to €20.8 billion for the collaboration.
EU Commission Approves Pfizer’s Takeover of Seagen
The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.
Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland
Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.
Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC
Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi XDC on the Hong Kong Stock Exchange. Upon completion of the proposed listing, Wuxi XDC will remain a consolidated subsidiary.
Olon Builds Second Plant for Ultra-Potent Compounds
Italian API producer Olon has started building a second facility at its Rodano site in Milan that will be entirely dedicated to producing ultra-potent compounds.
BioNTech and DualityBio Sign ADC Rights Deal
German biotech and Covid vaccine maker BioNTech has sealed a major deal with Chinese biotech DualityBio to co-develop and commercialize two cancer antibody drug candidates (ADCs).
Pfizer Takes Seagen for $43 Billion
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.
Integrated Drug Development Models
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
Managing Supply for Complex Biotherapeutics
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process and access to a range of large- and small-molecule manufacturing assets.
Catalent and Exelixis Link on ADCs
US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood Bioscience subsidiary will use its proprietary SMARTag site-specific bioconjugation technology to build ADCs using monoclonal antibodies from Exelixis’ preclinical pipeline.
The Rise of HPAPI Molecules
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
